PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC MutationsX. Le, J. Wang, H. Hayashi et al.|Journal of Thoracic Oncology|2024Cited by 14
LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05M-J. Ahn, Weili Gu, Jacob Sands et al.|Annals of Oncology|2024Cited by 9
MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II StudyGeoffrey Liu, Lyudmila Bazhenova, Nengcong Yang et al.|Journal of Thoracic Oncology|2024Cited by 4
MA02.02 Updated Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II StudyGeoffrey Liu, Lyudmila Bazhenova, C.-M. Choi et al.|Journal of Thoracic Oncology|2025Cited by 3